Tango Discontinuation of TNG348 Program

 – The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts –

– Cash runway extended into 2027, PRMT5 and CoREST clinical programs remain on track –

https://www.businesswire.com/news/home/20240523266195/en/